摘要:
Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
摘要:
Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
摘要:
Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
摘要:
Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
摘要:
An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells.
摘要:
An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells.
摘要:
An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells.
摘要:
The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.
摘要翻译:本发明提供新型固体癌抗原蛋白,以及用于固体癌的诊断试剂盒和基于抗原蛋白质的固体癌治疗剂。 具体地说,本发明提供具有选自SEQ ID NOS:2,4,6,8,10,12,14,16,18,20,22,24的氨基酸序列的人类固体癌抗原多肽 ,26,28,30,32,34,36,38,40,42,44,48,50,52,54,56,59,61,63,65,67,69,71,73和75。